Kamila Alexova-Zurkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamila Alexova-Zurkova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jan Vydra
Institute of Hematology and Blood Transfusion, Prague, Czechia
1 shared publication - Jana Mackova
Institute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic
1 shared publication - Jitka Krystofova
Institute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic
1 shared publication - Katerina Roubalova
Institute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic
1 shared publication - Marketa Markova
Department of Haematology and Blood Transfusion, University Hospital Na Bulovce, 128 00 Prague, Czech Republic
1 shared publication - Milena Vrana
Department of HLA, Institute of Hematology and Blood Transfusion, Prague, Czechia
1 shared publication
Latest Publications
- Open Access
- 20 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 2928-2934
Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to the re-localization of the NPM1 protein from the nucleolus to the cytoplasm (NPM1c+). NPM1c+ is found in 30% of acute myeloid leukemia (AML). Our study showed that an AML patient, whose leukemia cells carried the NPM1c+ mutation and who was the recipient of allogeneic HSCT from a haploidentical donor, raised a robust allorestricted CD8+ T cell response directed against the NPM1wt protein. Favourably, the response against NPM1wt was not accompanied by side effects such as GvHD. Moreover, the induction of a high NPM1wt-specific response coincided with the decrease in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of grafts from haploidentical donors as a possible tool for TCR gene therapy.
- 20 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 2928-2934
Open AccessNon-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to the re-localization of the NPM1 protein from the nucleolus to the cytoplasm (NPM1c+). NPM1c+ is found in 30% of acute myeloid leukemia (AML). Our study showed that an AML patient, whose leukemia cells carried the NPM1c+ mutation and who was the recipient of allogeneic HSCT from a haploidentical donor, raised a robust allorestricted CD8+ T cell response directed against the NPM1wt protein. Favourably, the response against NPM1wt was not accompanied by side effects such as GvHD. Moreover, the induction of a high NPM1wt-specific response coincided with the decrease in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of grafts from haploidentical donors as a possible tool for TCR gene therapy.